Day: August 19, 2020

Corona is an official cerveza of the Los Angeles Rams and the brand-new SoFi StadiumPacifico is an official beer of the Los Angeles Chargers and the brand-new SoFi StadiumModelo is an official cerveza of the Las Vegas Raiders and the brand-new Allegiant StadiumWoodbridge by Robert Mondavi is the official wine of the Las Vegas RaidersVICTOR, N.Y., Aug. 19, 2020 (GLOBE NEWSWIRE) — As fans prepare for the return of sports, Constellation Brands announces multi-year partnerships with professional football teams and stadiums to bring engaging experiences featuring their favorite beer and wine. Corona, Pacifico, Modelo, and Woodbridge by Robert Mondavi are proud supporters of several teams and two new stadiums – including the Los Angeles Rams, the Los Angeles Chargers and SoFi Stadium, the Las Vegas Raiders and Allegiant Stadium. Brands...

AB Ignitis Grupė, (hereinafter – the Company, Ignitis Grupė) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 900 000 000 EUR; ISIN codes XS1646530565; XS1853999313; XS2177349912.The Company informs that the mandatory buyout of shares of its subsidiary AB Ignitis gamyba (hereinafter – GEN) was finished on 17 August 2020. Completed transactions was settled on 19 August 2020, i.e. the second day following the conclusion of the transaction.The Company informs that during the period of the mandatory buyout, which lasted from 18 May 2020 to 17 August 2020, 4 859 782 (four million eight hundred fifty-nine thousand seven hundred and eighty-two) shares of GEN were buyout, which equals to 0.75 % of the authorized capital of GEN.After the mandatory...

AB „Ignitis grupė“ (toliau – Bendrovė, „Ignitis grupė“), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra AB „Ignitis grupė“ išleistų obligacijų nominali vertė 900 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313; XS2177349912.Bendrovė informuoja, kad 2020 m. rugpjūčio 17 d. baigė privalomą dukterinės bendrovės AB „Ignitis gamyba“ (toliau – GEN) akcijų išpirkimą, pagal kurį už įvykdytus akcijų pardavimo sandorius atsiskaitė šiandien, rugpjūčio 19 d., t. y. antrą dieną po sandorio sudarymo.  Privalomo akcijų išpirkimo laikotarpiu nuo 2020 m. gegužės 18 d. iki 2020 m. rugpjūčio 17 d. buvo supirktos 4 859 782 (keturi milijonai aštuoni šimtai penkiasdešimt devyni tūkstančiai septyni šimtai aštuoniasdešimt dvi) GEN akcijos. Jos sudaro 0,75 proc. GEN įstatinio kapitaloPasibaigus privalomam GEN...

Schlieren/Switzerland, 18 August 2020The news release can be downloaded from the following link:AttachmentRelease

伊利诺伊州威尔美特和威斯康辛州贝洛伊特及加利福尼亚州摩根山, Aug. 19, 2020 (GLOBE NEWSWIRE) —  正在合作开发尿激酶型纤溶酶原激活物受体靶向放射科免疫疗法（RIT）用于治疗重症新冠肺炎患者的Monopar Therapeutics Inc.（纳斯达克：MNPR）（伊利诺伊州威尔美特）和NorthStar Medical Radioisotopes, LLC（威斯康辛州贝洛伊特）今天宣布，与专注于加速临床前生物产品开发的领先合同研究组织Aragen Bioscience, Inc.（加利福尼亚州摩根山）建立合作伙伴关系。Aragen将进行旨在选择主要候选uPRIT的研究，以推进至重症新冠肺炎的试验性新药开发阶段。“Aragen在这一特定领域临床前研究的专业知识将加速基于MNPR-101抗体支架对主要uPRIT的选择，以推进到临床阶段，”Monopar首席科学官Andrew Mazar博士表示。“我们很高兴在uPRIT计划的这一重要阶段与Aragen开展合作，”NorthStar高级副总裁兼首席科学官James T. Harvey博士说到， “使用严格标准来选择uPRIT候选药物以推进到试验性新药研究阶段，这是我们新冠肺炎计划的一个关键部分。”“uPRIT对于重症新冠肺炎患者具有巨大的治疗潜力，”Aragen首席执行官Axel Schleyer博士表示， “我们很高兴能与Monopar和NorthStar合作进行这项重要工作。”此次合作的目的是识别具有最佳尿激酶型纤溶酶原激活物受体结合性的uPRIT，从而能够将细胞毒性放射性同位素有选择性地运送到产生“细胞因子风暴”的异常激活免疫细胞，正是这些细胞造成了重症新冠肺炎患者的严重肺部损伤、多器官损伤和死亡。关于Monopar Therapeutics Inc.Monopar Therapeutics是一家临床阶段生物制药公司，主要专注于开发延长癌症患者寿命或提高其生活质量的专有疗法。Monopar处于不同研发阶段的产品包括：用于预防口咽癌症患者因化疗引起严重口腔黏膜炎的Validive®；用于治疗晚期软组织肉瘤的camsirubicin；以及用在晚期癌症和重症新冠肺炎的后期临床前抗体MNPR-101。如需获取更多信息，请访问：www.monopartx.com。关于NorthStar...

Fort Lauderdale, FL, Aug. 19, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — MediXall Group Inc. (OTCQB: MDXL), a technology and innovation-driven organization focused on reducing healthcare costs and transforming the patient-provider experience through the launch of its Health Karma™ platform, is pleased to announce the formation of their Health Insurance Advisory Board with the appointment of Don Mathern as a non-executive director. Don brings more than 45 years of comprehensive healthcare expertise and relationships from the individual and employer health insurance market segments and will provide guidance to help support and shape continuing innovation at MediXall Group. Specifically, Don will provide guidance and support on strategic initiatives as the Company accelerates business growth, expands its services, and strives...